| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies.
|
Blood
|
2008
|
3.33
|
|
2
|
Influence of infused cell dose and HLA match on engraftment after double-unit cord blood allografts.
|
Blood
|
2010
|
2.73
|
|
3
|
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.
|
Blood
|
2011
|
2.68
|
|
4
|
Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial.
|
Lancet
|
2005
|
2.61
|
|
5
|
A scheme for defining cause of death and its application in the T cell depletion trial.
|
Biol Blood Marrow Transplant
|
2007
|
1.89
|
|
6
|
Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome.
|
Biol Blood Marrow Transplant
|
2009
|
1.87
|
|
7
|
Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities.
|
Biol Blood Marrow Transplant
|
2010
|
1.83
|
|
8
|
Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.
|
Blood
|
2002
|
1.79
|
|
9
|
Results of the cord blood transplantation (COBLT) study unrelated donor banking program.
|
Transfusion
|
2005
|
1.78
|
|
10
|
Cord blood units with low CD34+ cell viability have a low probability of engraftment after double unit transplantation.
|
Biol Blood Marrow Transplant
|
2009
|
1.74
|
|
11
|
T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin.
|
Blood
|
2007
|
1.73
|
|
12
|
T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2011
|
1.71
|
|
13
|
Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
1.65
|
|
14
|
HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia.
|
J Clin Oncol
|
2009
|
1.65
|
|
15
|
Characterization of banked umbilical cord blood hematopoietic progenitor cells and lymphocyte subsets and correlation with ethnicity, birth weight, sex, and type of delivery: a Cord Blood Transplantation (COBLT) Study report.
|
Transfusion
|
2005
|
1.56
|
|
16
|
Direct evidence for new T-cell generation by patients after either T-cell-depleted or unmodified allogeneic hematopoietic stem cell transplantations.
|
Blood
|
2002
|
1.53
|
|
17
|
Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
1.50
|
|
18
|
Paroxysmal nocturnal hemoglobinuria in pediatric patients.
|
Pediatr Blood Cancer
|
2011
|
1.49
|
|
19
|
Prospective grading of graft-versus-host disease after unrelated donor marrow transplantation: a grading algorithm versus blinded expert panel review.
|
Biol Blood Marrow Transplant
|
2003
|
1.48
|
|
20
|
Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases.
|
Biol Blood Marrow Transplant
|
2006
|
1.45
|
|
21
|
Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program.
|
Biol Blood Marrow Transplant
|
2008
|
1.44
|
|
22
|
T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2012
|
1.42
|
|
23
|
The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2008
|
1.42
|
|
24
|
Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2007
|
1.39
|
|
25
|
Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
|
Biol Blood Marrow Transplant
|
2010
|
1.34
|
|
26
|
A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2013
|
1.32
|
|
27
|
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
|
Biol Blood Marrow Transplant
|
2013
|
1.25
|
|
28
|
Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.
|
Blood
|
2005
|
1.18
|
|
29
|
Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
|
Biol Blood Marrow Transplant
|
2005
|
1.17
|
|
30
|
Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings.
|
Biol Blood Marrow Transplant
|
2008
|
1.13
|
|
31
|
Individual physician practice variation in hematopoietic cell transplantation.
|
J Clin Oncol
|
2008
|
1.11
|
|
32
|
Antigen-specific T-lymphocyte function after cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2006
|
1.08
|
|
33
|
Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia.
|
Br J Haematol
|
2008
|
1.03
|
|
34
|
Fludarabine-based conditioning secures engraftment of second hematopoietic stem cell allografts (HSCT) in the treatment of initial graft failure.
|
Biol Blood Marrow Transplant
|
2007
|
0.99
|
|
35
|
Variation in supportive care practices in hematopoietic cell transplantation.
|
Biol Blood Marrow Transplant
|
2008
|
0.97
|
|
36
|
Recent decrease in acute graft-versus-host disease in children with leukemia receiving unrelated donor bone marrow transplants.
|
Biol Blood Marrow Transplant
|
2009
|
0.96
|
|
37
|
Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma.
|
Pediatr Blood Cancer
|
2010
|
0.94
|
|
38
|
Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.
|
Biol Blood Marrow Transplant
|
2007
|
0.92
|
|
39
|
Drug safety evaluation of defibrotide.
|
Expert Opin Drug Saf
|
2012
|
0.92
|
|
40
|
Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT).
|
Biol Blood Marrow Transplant
|
2008
|
0.88
|
|
41
|
Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience.
|
Pediatr Blood Cancer
|
2012
|
0.86
|
|
42
|
Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants.
|
Blood
|
2006
|
0.84
|
|
43
|
Ten-year follow-up of pediatric patients with non-Hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation.
|
Pediatr Blood Cancer
|
2013
|
0.83
|
|
44
|
The use of back-up units to enhance the safety of unrelated donor cord blood transplantation.
|
Biol Blood Marrow Transplant
|
2012
|
0.83
|
|
45
|
Allogeneic hematopoietic stem cell transplantation for pediatric patients with treatment-related myelodysplastic syndrome or acute myelogenous leukemia.
|
Biol Blood Marrow Transplant
|
2011
|
0.82
|
|
46
|
Safety and immunogenicity of the live attenuated varicella vaccine following T replete or T cell-depleted related and unrelated allogeneic hematopoietic cell transplantation (alloHCT).
|
Biol Blood Marrow Transplant
|
2011
|
0.81
|
|
47
|
Incidence, nature and mortality of cytomegalovirus infection after double-unit cord blood transplant.
|
Leuk Lymphoma
|
2014
|
0.81
|
|
48
|
Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy.
|
J Clin Oncol
|
2008
|
0.81
|
|
49
|
Splenic infarction and subsequent splenic rupture in a patient with paroxysmal nocturnal hemoglobinuria and heparin-induced thrombocytopenia.
|
Pediatr Blood Cancer
|
2009
|
0.80
|
|
50
|
Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation.
|
Biol Blood Marrow Transplant
|
2011
|
0.78
|